Point-of-Care Lipid Test Industry Set to Hit $1.23 Billion by 2033, Growing at 6.8% CAGR | Exclusive Data Like Latest M & A, Regulatory Approvals, FDA Approvals, Latest Investments, Reimbursements

The global point-of-care (POC) lipid test market reached US$ 0.68 billion in 2023, with a rise to US$ 0.72 billion in 2024, and is expected to reach US$ 1.23 billion by 2033, growing at a CAGR of 6.8% during the forecast period 2025-2033

DataM Intelligence has published a new research report on "Point-of-Care POC Lipid Test Market Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

Key Points:

2024 Market Size: US$ 0.72 Billion
2033 Projected Market Size: US$ 1.23 Billion
CAGR (2025-2033): 6.8%
North America: Largest market in 2024
Asia Pacific: Fastest-growing market

Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/point-of-care-poc-lipid-test-market?rk

Recent M&A and Strategic Collaborations:

Strategic partnerships are driving market penetration, such as PTS Diagnostics partnering with a major US pharmacy chain to scale lipid screening services, and SD Biosensor launching next-gen microfluidic platforms.​

Large diagnostic companies are actively acquiring smaller, innovative POC lipid players to expand portfolios and leverage rapid technology integration, consolidating market positions and fast-tracking commercialization of new offerings.

Key Players:

Abbott, F. Hoffmann-La Roche Ltd, Siemens Healthcare Private Limited (Siemens Healthineers AG), SD Biosensor, INC., ACON Laboratories, Inc., PTS Diagnostics, Woodley Equipment Company Ltd, among others.

Key Development:

United States: Key Developments

In October 2025, Abbott Laboratories received FDA clearance for its rapid lipid panel test, delivering results in under 5 minutes and supporting more immediate cardiovascular risk assessment in clinical and retail settings.​

The American Heart Association updated guidelines in October 2025 to recommend routine point-of-care lipid testing in primary care, accelerating use in clinics and community health centers.​

A major US pharmacy chain launched lipid testing stations at over 2,000 retail locations in October 2025, improving accessibility for preventive screening and routine check-ups for cardiovascular risk.​

Widespread adoption of POC lipid tests in the US is supported by advanced biosensor technologies, seamless integration with electronic health records (EHRs), and robust healthcare infrastructure.​

Heska Corporation expanded its POC lipid offerings with the acquisition of MBio Diagnostics, strengthening its position in rapid-test diagnostics in early 2023.​

North America maintains the largest market share in POC lipid testing globally (about 44-45%), reflecting high cardiovascular disease prevalence and ongoing investments in decentralized healthcare models.​

Japan: Key Developments:

In October 2025, Roche Diagnostics launched a compact POC lipid device with cloud connectivity, allowing remote patient monitoring and enhancing data integration for cardiovascular risk management.​

Japan's Ministry of Health approved point-of-care lipid testing for workplace health screenings, supporting nationwide rollouts aimed at preventing metabolic syndrome and related conditions among employees.​

Sysmex Corporation developed a multi-parameter testing system that integrates lipid profiles with other cardiovascular biomarkers, facilitating more comprehensive risk evaluation in a single test.​

The Japanese POC lipid test market is projected to grow at a CAGR of about 6.5% to 7.9% till 2033, fueled by an aging population, government support for preventive care, and adoption of new microfluidic platforms for higher test accuracy.​

Mobile POC devices and decentralized diagnostic services are seeing rapid uptake in Japan, with pharmacies and clinics leading the distribution

Growth Forecast Projected:

The Global Point-of-Care POC Lipid Test Market Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Regulatory and FDA Approvals:

M&A activity is partly influenced by regulatory developments like the EU's IVDR regulations and FDA's demand for robust performance in CLIA-waived devices-these raise standards but also extend market entry timelines.​

In mid-2025, the FDA cleared the Tina-quant® Lipoprotein (a) Gen.2 assay for POC use, allowing clinicians direct access for hereditary risk factor assessment at the bedside.​

Roche Diagnostics secured CE Mark approval under IVDR for its multi-analyte lipid testing system, ensuring regulatory compliance and continued EU market access.​

New CDC certification protocols are tightening accuracy and precision requirements for POC lipid tests, solidifying the reliability of clinical data versus centralized labs.

Research Process:

Both primary and secondary data sources have been used in the global Point-of-Care POC Lipid Test Market Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=point-of-care-poc-lipid-test-market?rk

Key Segments:

By Product Type:
Instruments | Consumables

By Disease Indication:
Hyperlipidemia | Hypercholesterolaemia | Tangier Disease | Hyperlipoproteinemia | Familial Hypercholesterolemia | Others

By Application:
Research and Development | Diagnostics | Biotechnological Product Manufacturing | Agriculture | Others

By End-User:
Pharmaceutical & Biotechnology Companies | Contract Development & Manufacturing Organizations (CDMOs) | Diagnostic Laboratories & Clinical Research Centers | Others

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Latest Investments:

Nova Biomedical notably expanded US manufacturing capacity to meet rising demand, indicating investor confidence in the long-term trajectory of rapid lipid and metabolic testing devices.​

The sector sees robust investment in digital health platforms and multi-analyte systems, with researchers at IIT Guwahati pioneering nanotech-enabled high-precision cholesterol and triglyceride detection.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/point-of-care-poc-lipid-test-market

Reimbursement Trends:

Adoption in community clinics and pharmacies is accelerating, particularly in rural and underserved areas, with growing support from insurers and public health agencies for decentralized screening.​

Improved POC test accuracy and integration with chronic disease management platforms are making it easier for payers to endorse reimbursement for preventative lipid screening in both traditional and retail settings.

Request 2 Days Free Trials with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.